SCHEMBL24745337

SCHEMBL24745337

Cc1c(-c2cccc3c(CCCOc4cccc5ccccc45)c(C(=O)OC(C)(C)C)[nH]c23)c(CO[Si](C)(C)C(C)(C)C)nn1C

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 20/20 0.68
EEF2K O00418 1/20 0.62
MARK3 P27448 1/20 0.62
AXL P30530 1/20 0.62
BCL6 P41182 1/20 0.62
NEK4 P51957 1/20 0.62
PRKCD Q05655 1/20 0.62
PRKAA1 Q13131 1/20 0.62
CAMK2B Q13554 1/20 0.62
CAMK2G Q13555 1/20 0.62
CAMK2D Q13557 1/20 0.62
MARK2 Q7KZI7 1/20 0.62
PIM3 Q86V86 1/20 0.62
HIPK2 Q9H2X6 1/20 0.62
MKNK2 Q9HBH9 1/20 0.62
MAP3K20 Q9NYL2 1/20 0.62
MAP4K5 Q9Y4K4 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30000669 1.00 MCL1 (0.68) MCL1EEF2KMARK3AXLBCL6
SCHEMBL24744726 0.87 MCL1 (0.80) MCL1EEF2KMARK3AXLBCL6
SCHEMBL30000956 0.87 MCL1 (0.80) MCL1EEF2KMARK3AXLBCL6
SCHEMBL21802262 0.85 MCL1 (0.57) MCL1EEF2KMARK3AXLBCL6
SCHEMBL24745138 0.85 MCL1 (0.58) MCL1EEF2KMARK3AXLBCL6
SCHEMBL28656361 0.84 MCL1 (0.68) MCL1EEF2KMARK3AXLBCL6
SCHEMBL28658541 0.83 MCL1 (0.55) MCL1EEF2KMARK3AXLBCL6
SCHEMBL4158609 0.82 MCL1 (0.72) MCL1EEF2KMARK3AXLBCL6
SCHEMBL19615331 0.82 MCL1 (0.62) MCL1EEF2KMARK3AXLBCL6
SCHEMBL28643079 0.81 MCL1 (0.52) MCL1EEF2KMARK3AXLBCL6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 CN disclosed
WO-2022255888-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 WO disclosed
WO-2022253713-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 WO disclosed